RESUMEN
Lysosomal storage diseases are inherited or acquired disorders characterized by dysfunctional lysosomes that lead to intracytoplasmic accumulation of undegraded substrates, causing impaired cellular function and death. Many acquired lysosomal storage diseases are produced by toxic plants, which have indolizidine alkaloids, including swainsonine, that inhibits lysosomal α-mannosidase and Golgi α-mannosidase II. Swainsonine-induced nervous disease associated with various plants has been reported, including species of the genus Astragalus, Sida, Oxitropis, Swainsona, and Ipomoea. Two species of Astragalus (i.e. Astragalus garbancillo and Astragalus punae) have been found to cause neurologic disease in llamas. In addition, A. garbancillo was also associated with malformations in the offspring, and possibly abortions and neonatal mortality in llamas. The diagnosis of Astragalus spp. intoxication is established based on clinical signs, microscopic and ultrastructural findings, lectin histochemistry, abundance of these plants in the grazing area and determination of swainsonine in plant specimens.
Asunto(s)
Planta del Astrágalo , Swainsonina , Animales , Planta del Astrágalo/química , Enfermedades por Almacenamiento Lisosomal/veterinaria , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Intoxicación por Plantas/veterinaria , Femenino , MasculinoRESUMEN
Drug-induced phospholipidosis (DIPLD) represents a big concern for both regulatory authorities and pharmaceutical companies in drug discovery. Many researches pointed out that the negatively charged intralysosomal lipids play an important role in the formation of DIPLD. To better mimic this negatively charged lipid surface, a novel immobilized artificial membrane (IAM) column was prepared via in situ copolymerization of 12-methacryloyl n-dodecylphosphocholine (MDPC) and 12-methacryloyl n-dodecylphosphoric acid (MDPA). By introducing MDPA, the surface of the resulting monolithic column can be maintained negatively charged over a broad pH range. Scanning electron microscopy, elemental analysis and nano-HPLC experiments were carried out to characterize the physicochemical properties and chromatographic performance of the obtained monolithic IAM column. The results of ζ-potential and retention mechanism studies indicate that both hydrophobic and electrostatic interactions contribute greatly to the retention of cation analytes owing to the existence of the negatively charged MDPA under acidic conditions. To better assess the DIPLD potency of drug, the molar ratio between MDPC and MDPA in the monolithic column was carefully optimized. The results show that the poly(MDPC70PA30-co-EDMA) column has the best predictability with only two false-positives (donepezil, flecainide) in qualitative analysis of 61 drugs.
Asunto(s)
Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Membranas Artificiales , Preparaciones Farmacéuticas , Fosfolípidos , Química Farmacéutica , Cromatografía Líquida de Alta Presión , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Microscopía Electrónica de Rastreo , Preparaciones Farmacéuticas/análisis , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/metabolismo , Ácidos Fosfatidicos , Fosfolípidos/química , Fosfolípidos/metabolismo , Electricidad EstáticaRESUMEN
The analysis of large numbers of cells from a population results in information that does not reflect differences in cell phenotypes. Individual variations in cellular drug uptake, metabolism, and response to drug treatment may have profound effects on cellular survival and lead to the development of certain disease states, drug persistence, and resistance. Herein, we present a method that combines live cell confocal microscopy imaging with high-resolution mass spectrometry to achieve absolute cell quantification of the drug amiodarone (AMIO) and its major metabolite, N-desethylamiodarone (NDEA), in single liver cells (HepG2 and HepaRG cells). The method uses a prototype system that integrates a confocal microscope with an XYZ stage robot to image and automatically sample selected cells from a sample compartment, which is kept under growth conditions, with nanospray tips. Besides obtaining the distributions of AMIO and NDEA cell concentrations across a population of individual cells, as well as variabilities in drug metabolism, the effect of these on phospholipidosis and cell morphology was studied. The method was suited to identify subpopulations of cells that metabolized less drug and to correlate cell drug concentrations with cell phospholipid content, cell volume, sphericity, and other cell phenotypic features. Using principal component analysis (PCA), the treated cells could be clearly distinguished from vehicle control cells (0 µM AMIO) and HepaRG cells from HepG2 cells. The potential of using multidimensional and multimodal information collected from single cells to build predictive models for cell classification is demonstrated.
Asunto(s)
Amiodarona/efectos adversos , Amiodarona/metabolismo , Enfermedades por Almacenamiento Lisosomal/diagnóstico por imagen , Enfermedades por Almacenamiento Lisosomal/patología , Espectrometría de Masas , Microscopía Confocal/métodos , Análisis de la Célula Individual/métodos , Amiodarona/análogos & derivados , Células Hep G2 , Humanos , Enfermedades por Almacenamiento Lisosomal/inducido químicamenteRESUMEN
Phospholipidosis (PLD), the intracellular accumulation of phospholipids, is an adaptive response to toxic stimuli and serves as an important parameter in the biological assessment of compounds. Cationic amphiphilic drugs are the main inducers of PLD and may impair the function of alveolar macrophages. In vivo and in vitro models are used for PLD screening but the choice of the cellular model may be important because PLD develops in a cell- and species-specific manner. In this study, a panel of different staining (LysoSensor, Acridine Orange, Nile Red, HCS LipidTOX, LysoID) was evaluated in murine (DMBM-2, J774, RAW264.7) and human (THP-1, monocyte-derived macrophages from peripheral blood) cells to identify the most sensitive and easy to analyze staining method and to detect species-specific differences in the reaction pattern. Amiodarone and chloroquine served as inducers of PLD. High content screening was used to compare number, area, and intensity of the staining. Due to the fast staining protocol and the sensitivity of the detection, LysoID proved to be the most suitable dye of the testing. The lower induction of PLD by chloroquine reported in vivo was also seen in this study. THP-1 macrophages, followed by DMBM-2 cells, produced the most similar reaction pattern to human monocyte-derived macrophages.
Asunto(s)
Amiodarona/efectos adversos , Cationes/efectos adversos , Cloroquina/efectos adversos , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Fosfolípidos/metabolismo , Animales , Línea Celular , Humanos , Enfermedades por Almacenamiento Lisosomal/metabolismo , Ratones , Monocitos/efectos de los fármacos , Células RAW 264.7 , Células THP-1RESUMEN
Aim: Our objective was to develop and qualify a bioanalytical method for the estimation of di-18:1-bis(monoacylglycero)phosphate (di-18:1 BMP) as a urinary biomarker for the assessment of drug-induced phospholipidosis and demonstrate its application in a preclinical study. Methodology/results: di-18:1 BMP was extracted by liquid-liquid extraction using n-butanol and analyzed by LC-MS/MS. The qualified method was selective, precise, robust and accurate across the linearity range (0.2-250 ng/ml). Qualified method was then used to assess chloroquine-induced phospholipidosis in rats dosed at 120 mg/kg for 5 days. A fivefold increase in di-18:1 BMP was observed on Day 5 compared with predose. Conclusion: Di-18:1 BMP can be used as a noninvasive biomarker to assess/screen compounds that could cause drug-induced phospholipidosis in rats.
Asunto(s)
Biomarcadores/orina , Cromatografía Liquida/métodos , Lisofosfolípidos/orina , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Monoglicéridos/orina , Fosfolípidos/metabolismo , Esfingolipidosis/inducido químicamente , Espectrometría de Masas en Tándem/métodos , Animales , Humanos , Enfermedades por Almacenamiento Lisosomal/orina , Masculino , Ratas , Ratas Sprague-Dawley , Esfingolipidosis/orinaRESUMEN
INTRODUCTION: This case report signifies the need to systemically assess antimalarial toxicity in those undergoing long-term treatment. CASE REPORT: A 59-year-old man with a history of ischemic-labeled heart disease revealed by conduction disorders and cutaneous lupus treated initially with hydroxychloroquine followed by chloroquine consulted for asthenia and weight loss. Clinically, he had a muscular atrophy, a motor deficit, and an abolition of the osteo-tendinous reflexes in the lower limbs. Adverse drug effects of the antimalarial therapy were suspected-specifically, muscular and cardiac toxicity. The diagnosis was confirmed with a muscle biopsy, which showed typical and florid vacuolar myopathy. Cessation of the drug resulted in a slow regression of symptoms. CONCLUSION: Cardiac and muscular toxicity related to antimalarials are rare and sometimes fatal; thus, they must be systematically assessed in a patient with several years of exposure. A muscle biopsy could be sufficient to allow for the diagnosis.
Asunto(s)
Antimaláricos/efectos adversos , Astenia , Cardiotoxicidad/diagnóstico , Enfermedades Musculares/inducido químicamente , Enfermedades Musculares/diagnóstico , Pérdida de Peso , Astenia/inducido químicamente , Astenia/diagnóstico , Biopsia , Cardiotoxicidad/etiología , Cardiotoxicidad/patología , Diagnóstico Diferencial , Humanos , Hidroxicloroquina/efectos adversos , Cuidados a Largo Plazo , Lupus Eritematoso Sistémico/inducido químicamente , Lupus Eritematoso Sistémico/diagnóstico , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Enfermedades por Almacenamiento Lisosomal/diagnóstico , Masculino , Persona de Mediana Edad , Músculos/patología , Enfermedades Musculares/patología , Pérdida de Peso/efectos de los fármacosRESUMEN
Drug-induced phospholipidosis is a lysosomal storage disorder characterized by excessive accumulation of phospholipids. Its cellular mechanism is still not well understood, but it is known that cationic amphiphilic drugs can induce it. These drugs have a hydrophilic amine head group that can be protonated in the endolysosomal compartment. As cationic amphiphiles, they are trapped in lysosomes, where they interfere with negatively charged intralysosomal vesicles, the major platforms of cellular sphingolipid degradation. Metabolic principles observed in sphingolipid and phospholipid catabolism and inherited sphingolipidoses are of great importance for lysosomal function and physiological lipid turnover at large. Therefore, we also propose intralysosomal vesicles as major platforms for degradation of lipids and phospholipids reaching them by intracellular pathways like autophagy and endocytosis. Phospholipids are catabolized as components of vesicle surfaces by protonated, positively charged phospholipases, electrostatically attracted to the negatively charged vesicles. Model experiments suggest that progressively accumulating cationic amphiphilic drugs inserting into the vesicle membrane with their hydrophobic molecular moieties disturb and attenuate the main mechanism of lipid degradation as discussed here. By compensating the negative surface charge, cationic enzymes are released from the surface of vesicles and proteolytically degraded, triggering a progressive lipid storage and the formation of inactive lamellar bodies.
Asunto(s)
Metabolismo de los Lípidos/genética , Enfermedades por Almacenamiento Lisosomal/genética , Fosfolípidos/metabolismo , Esfingolipidosis/genética , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Lípidos/química , Lípidos/genética , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Enfermedades por Almacenamiento Lisosomal/metabolismo , Enfermedades por Almacenamiento Lisosomal/patología , Lisosomas/genética , Lisosomas/metabolismo , Orgánulos/metabolismo , Fosfolípidos/genética , Esfingolipidosis/inducido químicamente , Esfingolipidosis/metabolismo , Esfingolipidosis/patologíaRESUMEN
Di-docosahexaenoyl (C22:6)-bis(monoacylglycerol) phosphate (BMP) has been identified as a promising biomarker for drug-induced phospholipidosis (DIPL). Both unlabelled and stable isotope labelled versions of BMP were desired for use as internal standards. Isopropylideneglycerol was converted to 4-methoxyphenyldiphenylmethyl-3-PMB-glycerol in three steps. Initially, the 2-postion of the glycerol was protected as a t-butyldiphenylsilyl ether, which proved to be a mistake; deprotection of the ether resulted in the decomposition of the compound. A switch to a t-butyldimethylsilyl ether protecting group resulted in an intermediate that could be deprotected to the alcohol to give the target compound after salt exchange. The same procedure was used to prepare [13 C6 ]BMP from [13 C3 ]glycerol.
Asunto(s)
Isótopos de Carbono/química , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Enfermedades por Almacenamiento Lisosomal/metabolismo , Monoglicéridos/química , Fosfatos/química , Fosfatos/síntesis química , Fosfolípidos/metabolismo , Técnicas de Química Sintética , Marcaje Isotópico , RadioquímicaRESUMEN
Cigarette smoke is known to be associated with the incidence of a variety of pulmonary diseases, and alveolar macrophages are a key player in the defense mechanism against inhalable toxicants. Herein, we have found that a hydrophilic fraction in smoke extracts from 3R4F reference cigarettes (CSE) contains high concentrations of volatile substances compared to cigarette smoke condensate (amphoteric fraction). We also identified the toxic mechanism of CSE using MH-S, a mouse alveolar macrophage cell line. CSE decreased cell viability accompanying increased lactate dehydrogenase release. Additionally, mitochondrial volume and the potential increased along with enhanced expression of mitochondrial fusion proteins and decreased adenosine triphosphate production. Similarly, CSE clearly induced increase of catalase activity and intracellular calcium concentration and decrease of endoplasmic reticulum and lysosome volume at the highest dose. More interestingly, damaged organelles accumulated in the cytosol, and CSE-containing particles specifically penetrated to mitochondria. Meanwhile, any significant change in autophagy related protein expression was not found in CSE-treated cells. Subsequently, we evaluated the effects of CSE on secretion of inflammatory related cytokines and chemokines, considering the relationship between organelle damage and the disturbed immune response. Very importantly, we found that expression of innate and adaptive immunity related mediators is disrupted following CSE exposure. Taken together, we suggest that CSE may cause the accumulation of damaged organelles in the cytoplasm by impairing selective autophagic function. In addition, this accumulation is responsible for the inadequate ability of immune cells to repair the damage of lung tissue following exposure to CSE.
Asunto(s)
Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Macrófagos Alveolares/efectos de los fármacos , Nicotiana/efectos adversos , Humo/efectos adversos , Animales , Apoptosis/efectos de los fármacos , Autofagia/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Inflamación/etiología , Macrófagos Alveolares/metabolismo , Ratones , Mitocondrias/efectos de los fármacos , Mitocondrias/patología , Orgánulos/efectos de los fármacos , Orgánulos/metabolismo , Orgánulos/patología , Estrés Oxidativo/efectos de los fármacos , Especies Reactivas de Oxígeno/metabolismoRESUMEN
Drug-induced phospholipidosis is one of the major concerns in drug development and clinical treatment. The present study involved the use of a nontargeting lipidomic analysis with liquid chromatography-mass spectrometry to explore noninvasive blood biomarkers for hepatic phospholipidosis from rat plasma. We used three tricyclic antidepressants (clomipramine [CPM], imipramine [IMI], and amitriptyline [AMT]) for the model of phospholipidosis in hepatocytes and ketoconazole (KC) for the model of phospholipidosis in cholangiocytes and administered treatment for 3 and 28 days each. Total plasma lipids were extracted and measured. Lipid molecules contributing to the separation of control and drug-treated rat plasma in a multivariate orthogonal partial least squares discriminant analysis were identified. Four lysophosphatidylcholines (LPCs) (16:1, 18:1, 18:2, and 20:4) and 42:1 hexosylceramide (HexCer) were identified as molecules separating control and drug-treated rats in all models of phospholipidosis in hepatocytes. In addition, 16:1, 18:2, and 20:4 LPCs and 42:1 HexCer were identified in a model of hepatic phospholipidosis in cholangiocytes, although LPCs were identified only in the case of 3-day treatment with KC. The levels of LPCs were decreased by drug-induced phospholipidosis, whereas those of 42:1 HexCer were increased. The increase in 42:1 HexCer was much higher in the case of IMI and AMT than in the case of CPM; moreover, the increase induced by IMI was dose-dependent. Structural characterization determining long-chain base and hexose delineated that 42:1 HexCer was d18:1/24:0 glucosylceramide (GluCer). In summary, our study demonstrated that d18:1/24:0 GluCer and LPCs are potential novel biomarkers for drug-induced hepatic phospholipidosis.
Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/sangre , Glucosilceramidas/sangre , Hígado/metabolismo , Lisofosfatidilcolinas/sangre , Enfermedades por Almacenamiento Lisosomal/sangre , Amitriptilina , Animales , Conductos Biliares/metabolismo , Biomarcadores/sangre , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Cromatografía Liquida , Clomipramina , Análisis Discriminante , Modelos Animales de Enfermedad , Hepatocitos/metabolismo , Imipramina , Análisis de los Mínimos Cuadrados , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Enfermedades por Almacenamiento Lisosomal/diagnóstico , Masculino , Espectrometría de Masas , Metabolómica/métodos , Análisis Multivariante , Valor Predictivo de las Pruebas , RatasRESUMEN
Several drugs have been associated with the potential for drug-induced hepatic steatosis (DIHS) and/or phospholipidosis (DIPL), a lysosomal storage disorder. Drug-induced hepatic steatosis is generally a chronic but reversible affliction and may involve drug accumulation in the liver. Fat accumulation may be either macrovesicular or microvesicular in nature. Commonly used medications associated with DIHS include amiodarone, valproate, tamoxifen, methotrexate, and some chemotherapeutic and antiretroviral agents. Two recently approved medications for the treatment of hereditary homozygous hypercholesterolemia have also been noted to cause hepatic steatosis. For some compounds such as methotrexate and tamoxifen, the underlying metabolic risk factors such as obesity and metabolic syndrome may exacerbate their potential to cause DIHS and its progression. In this article, the authors discuss the preclinical screening and mechanisms of DIHS and DIPL, and review specific examples of drugs commonly used in clinical practice that are known to cause DIHS.
Asunto(s)
Hígado Graso/inducido químicamente , Hígado Graso/metabolismo , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Mitocondrias Hepáticas/metabolismo , Fosfolípidos/metabolismo , Amiodarona/efectos adversos , Animales , Antiarrítmicos/efectos adversos , Antirretrovirales/efectos adversos , Anticolesterolemiantes/efectos adversos , Anticonvulsivantes/efectos adversos , Antineoplásicos Hormonales/efectos adversos , Evaluación Preclínica de Medicamentos , Hígado Graso/patología , Humanos , Inmunosupresores/efectos adversos , Metotrexato/efectos adversos , Mitocondrias Hepáticas/efectos de los fármacos , Tamoxifeno/efectos adversos , Ácido Valproico/efectos adversosRESUMEN
Amphotericin B is a powerful polyene antifungal drug used for treating systemic fungal infections and is usually administered for a short period. Side effects after prolonged use are unknown in humans. Here we report the case of a 28-year-old man suffering from chronic granulomatous disease (CGD), treated for invasive cerebral aspergillosis with liposomal amphotericin B (L-AmB) for a very long time (8 consecutive years). We describe the efficacy and safety of this treatment in the long term. Aspergillosis was kept under control as long as L-AmB therapy was maintained, but relapsed when the dose was reduced. No overt renal toxicity was noted. The patient gradually developed hepatosplenomegaly and pancytopenia. Abnormalities of bone marrow were similar to the sea-blue histiocyte syndrome. Liver biopsy showed images of nodular regenerative hyperplasia related to CGD as well as a histiocytic storage disease. We discuss the very prolonged use of L-AmB leading to the development of a lysosomal storage disease.
Asunto(s)
Anfotericina B/efectos adversos , Anfotericina B/uso terapéutico , Antifúngicos/efectos adversos , Antifúngicos/uso terapéutico , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Adulto , Biopsia , Enfermedad Granulomatosa Crónica/complicaciones , Histocitoquímica , Humanos , Hígado/patología , Masculino , Neuroaspergilosis/tratamiento farmacológicoRESUMEN
Swainsonine, an indolizidine alkaloid with significant physiological activity, is an α-mannosidase and mannosidase II inhibitor that alters glycoprotein processing and causes lysosomal storage disease. Swainsonine is present in a number of plant species worldwide and causes severe toxicosis in livestock grazing these plants. Consumption of these plants by grazing animals leads to a chronic wasting disease characterized by weight loss, depression, altered behavior, decreased libido, infertility, and death. This review focuses on the three plant families and the associated taxa that contain swainsonine; the fungi that produce swainsonine, specifically the fungal endophytes associated with swainsonine-containing taxa; studies investigating the plant, endophyte, and swainsonine relationship; the influence of environmental factors on swainsonine concentrations in planta; and areas of future research.
Asunto(s)
Hongos/fisiología , Plantas Tóxicas/química , Swainsonina/química , Swainsonina/toxicidad , Simbiosis , Alimentación Animal/análisis , Animales , Planta del Astrágalo/química , Endófitos/metabolismo , Fabaceae/química , Fabaceae/clasificación , Hongos/clasificación , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Oxytropis/química , Intoxicación por Plantas/veterinaria , Semillas/química , Simbiosis/fisiologíaRESUMEN
Dental amalgam fillings are widely used all over the world. However, their mercury content can lead to various side effects and clinical problems. Acute or chronic mercury exposure can cause several side effects on the central nerve system, renal and hepatic functions, immune system, fetal development and it can play a role on exacerbation of neuromuscular diseases. In this case, we will present a patient with vacuolar myopathy whose symptoms were started and aggravated with her dental amalgam fillings.
Asunto(s)
Amalgama Dental/efectos adversos , Mercurio/toxicidad , Adulto , Femenino , Humanos , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Enfermedades Musculares/inducido químicamenteRESUMEN
Colchicine treatment is associated with an autophagic vacuolar myopathy in human patients. The presumed mechanism of colchicine-induced myotoxicity is the destabilization of the microtubule system that leads to impaired autophagosome-lysosome fusion and the accumulation of autophagic vacuoles. Using the MTOR inhibitor rapamycin we augmented colchicine's myotoxic effect by increasing the autophagic flux; this resulted in an acute myopathy with muscle necrosis. In contrast to myonecrosis induced by cardiotoxin, myonecrosis induced by a combination of rapamycin and colchicine was associated with accumulation of autophagic substrates such as LC3-II and SQSTM1; as a result, autophagic vacuoles accumulated in the center of myofibers, where LC3-positive autophagosomes failed to colocalize with the lysosomal protein marker LAMP2. A similar pattern of central LC3 accumulation and myonecrosis is seen in human patients with colchicine myopathy, many of whom have been treated with statins (HMGCR/HMG-CoA reductase inhibitors) in addition to colchicine. In mice, cotreatment with colchicine and simvastatin also led to muscle necrosis and LC3 accumulation, suggesting that, like rapamycin, simvastatin activates autophagy. Consistent with this, treatment of mice with four different statin medications enhanced autophagic flux in skeletal muscle in vivo. Polypharmacy is a known risk factor for toxic myopathies; our data suggest that some medication combinations may simultaneously activate upstream autophagy signaling pathways while inhibiting the degradation of these newly synthesized autophagosomes, resulting in myotoxicity.
Asunto(s)
Autofagia/fisiología , Colchicina/farmacología , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Enfermedades Musculares/inducido químicamente , Animales , Autofagia/efectos de los fármacos , Progresión de la Enfermedad , Humanos , Enfermedades por Almacenamiento Lisosomal/patología , Ratones , Ratones Endogámicos C57BL , Músculo Esquelético/efectos de los fármacos , Músculo Esquelético/patología , Músculo Esquelético/fisiopatología , Enfermedades Musculares/patología , Fagosomas/efectos de los fármacos , Fagosomas/patología , Simvastatina/farmacología , Regulación hacia Arriba/efectos de los fármacos , Vacuolas/efectos de los fármacos , Vacuolas/patologíaAsunto(s)
Hidroxicloroquina/efectos adversos , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Imagen por Resonancia Magnética/métodos , Enfermedades Musculares/inducido químicamente , Músculo Cuádriceps/efectos de los fármacos , Femenino , Humanos , Hidroxicloroquina/administración & dosificación , Persona de Mediana Edad , Músculo Cuádriceps/patologíaRESUMEN
Storage diseases are metabolic multiorgan conditions, which may be divided into lysosomal and nonlysosomal diseases. Disorders of the lysosomal type require electron microscopy for morphological diagnosis. It is the metabolic substrate that determines involvement of the cell type or organ in the individual storage disease, allowing extracerebral biopsies, for instance, in the neuronal ceroid-lipofuscinoses (NCL). A hierarchy of tissues biopsied for diagnosis can be based on easy accessibility: blood lymphocytes, skin, conjunctiva, rectum, skeletal muscle. Lysosomal diseases are divided into vacuolar and nonvacuolar ones. NCL display variegated ultrastructural patterns. Drugs may induce lysosomal storage. Finally, polyglucosan body diseases require attention.
Asunto(s)
Enfermedades por Almacenamiento Lisosomal/patología , Lisosomas/patología , Biopsia , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Humanos , Enfermedad de Lafora/patología , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Lisosomas/efectos de los fármacos , Lisosomas/ultraestructura , Microscopía Electrónica , Valor Predictivo de las Pruebas , Vacuolas/patologíaRESUMEN
BACKGROUND: The autophagic vacuolar myopathies (AVM) are a group of inherited myopathies defined by the presence of autophagic vacuoles in pathological muscle specimens. AVM can be categorized into three groups: acid maltase deficiency, myopathies characterized by autophagic vacuoles with unique sarcolemmal features, and rimmed vacuolar myopathies (RVM). While the pathogeneses of these conditions are still being elucidated, some drugs (e.g., chloroquine, its analog, hydroxychloroquine, and colchicine) can also cause AVM. Minocycline is a disease-modifying anti-rheumatic drug that may be used in the treatment of rheumatoid arthritis (RA). Here, we describe the first case of minocycline-associated AVM with rimmed vacuole formation. CASE PRESENTATION: A 75-year-old woman suffering from RA has been continuously treated with minocycline (200 mg/day) for the past 7 years. During this time, she developed a myopathy that predominantly affected her lower limbs. Histological studies of biopsied muscle revealed scattered atrophic myofibers with rimmed vacuoles that contained pigment granules. Histochemical staining revealed that the pigment comprised both iron and melanin, which is consistent with type II minocycline-induced cutaneous pigmentation. Under electron microscopy, autophagic vacuoles were consistently observed in association with numerous collections of pigment granules. CONCLUSIONS: This is the first report of minocycline-induced pigmentation in skeletal muscle. The strong association between autophagic vacuoles and the accumulation of minocycline-induced pigments suggest that long-term minocycline treatment induced pigment accumulation, leading to elevation of autophagic activity and RVM. It might also be possible that minocycline directly activated autophagy, as the observed pigments are known to form complexes containing minocycline and/or its metabolites. As long-term minocycline treatment is expected to be used more widely in the future, we must draw attention to this adverse effect.
Asunto(s)
Artritis Reumatoide/complicaciones , Artritis Reumatoide/tratamiento farmacológico , Enfermedades por Almacenamiento Lisosomal/inducido químicamente , Enfermedades por Almacenamiento Lisosomal/diagnóstico , Minociclina/efectos adversos , Minociclina/uso terapéutico , Enfermedades Musculares/inducido químicamente , Enfermedades Musculares/diagnóstico , Anciano , Antirreumáticos/efectos adversos , Antirreumáticos/uso terapéutico , Femenino , HumanosRESUMEN
Drug-induced phospholipidosis (PLD) is a lysosomal storage disorder characterized by the accumulation of phospholipids within the lysosome. This adverse drug effect can occur in various tissues and is suspected to impact cellular viability. Therefore, it is important to test chemical compounds for their potential to induce PLD during the drug design process. PLD has been reported to be a side effect of many commonly used drugs, especially those with cationic amphiphilic properties. To predict drug-induced PLD in silico, we established a high-throughput cell-culture-based method to quantitatively determine the induction of PLD by chemical compounds. Using this assay, we tested 297 drug-like compounds at two different concentrations (2.5â µM and 5.0â µM). We were able to identify 28 previously unknown PLD-inducing agents. Furthermore, our experimental results enabled the development of a binary classification model to predict PLD-inducing agents based on their molecular properties. This random forest prediction system yields a bootstrapped validated accuracy of 86 %. PLD-inducing agents overlap with those that target similar biological processes; a high degree of concordance with PLD-inducing agents was identified for cationic amphiphilic compounds, small molecules that inhibit acid sphingomyelinase, compounds that cross the blood-brain barrier, and compounds that violate Lipinski's rule of five. Furthermore, we were able to show that PLD-inducing compounds applied in combination additively induce PLD.